United States first country to launch Saxenda®

Posted: 22 Apr 2015 05:00 AM PDT

Novo Nordisk today announced that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada.

Researchers question use of paracetamol for lower back pain and osteoarthritis

Posted: 01 Apr 2015 02:00 AM PDT

New research shows that paracetamol is ineffective in reducing pain, disability or improving quality of life for patients who suffer from low back pain or osteoarthritis of the hip or knee, and its use may affect the liver. The study published in the British Medical Journal provides new evidence that paracetamol is no better at treating low back pain than a placebo and its effect on osteoarthritis of the hip or knee is too small to be clinically worthwhile.